FOLH1 and prostate carcinoma: This is consistent with data associating TSG mutations with shorter PSA50, PFS, and OS in patients receiving 177Lu-PSMA-617.16,17 This interplay underscores the complexity of prostate cancer progression and the need for alternative targeting strategies in advanced disease.